Ophthalix reports plans to price public offering of its common stock

Bookrunner Maxim Group also has a 45-day greenshoe for offering

By Devika Patel

Knoxville, Tenn., July 2 - Ophthalix Inc. will conduct a public offering of common stock with a 45-day greenshoe, according to a Form S-1 filed Tuesday with the Securities and Exchange Commission.

Maxim Group LLC is the bookrunning manager.

Proceeds will be used to conduct the clinical trials of CF101 for use in treating DES and glaucoma, to conduct the study for the development of CF101 for uveitis, to repay amounts owed to Can-Fite, to conduct additional preclinical studies of CF101, for the development of new drug candidates, for working capital and for other general corporate purposes.

The clinical-stage biopharmaceutical company is based in Petach Tikva, Israel.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.